Immune Correlate-Guided HIV Vaccine Design

Cell Host and Microbe

Volumn 24, Issue 1, 2018, Pages 25-33

  Alter, Galit ^a   Barouch, Dan ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; POLYCLONAL ANTIBODY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

DRUG DESIGN; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOLOGICAL PARAMETERS; INNATE IMMUNITY; NONHUMAN; PRIMATE; PRIORITY JOURNAL; REVIEW; VIRUS NEUTRALIZATION; ANIMAL; DISEASE MODEL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IMMUNOLOGY; VIROLOGY;

AIDS VACCINES; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV; HIV INFECTIONS; HUMANS; IMMUNITY; IMMUNITY, HUMORAL;

EID: 85049346187     PISSN: 19313128     EISSN: 19346069     Source Type: Journal    
DOI: 10.1016/j.chom.2018.06.012     Document Type: Review

References (117)

1. Ackerman, M.E., Crispin, M., Yu, X., Baruah, K., Boesch, A.W., Harvey, D.J., Dugast, A.S., Heizen, E.L., Ercan, A., Choi, I., et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123 (2013), 2183–2192.
2. Ackerman, M.E., Mikhailova, A., Brown, E.P., Dowell, K.G., Walker, B.D., Bailey-Kellogg, C., Suscovich, T.J., Alter, G., Polyfunctional HIV-specific antibody responses are associated with spontaneous HIV control. PLoS Pathog., 12, 2016, e1005315.
3. Anderson, D.J., Le Grand, R., Cell-associated HIV mucosal transmission: the neglected pathway. J. Infect. Dis. 210:Suppl 3 (2014), S606–S608.
4. Bale, J.B., Gonen, S., Liu, Y., Sheffler, W., Ellis, D., Thomas, C., Cascio, D., Yeates, T.O., Gonen, T., King, N.P., Baker, D., Accurate design of megadalton-scale two-component icosahedral protein complexes. Science 353 (2016), 389–394.
5. Barouch, D.H., Alter, G., Broge, T., Linde, C., Ackerman, M.E., Brown, E.P., Borducchi, E.N., Smith, K.M., Nkolola, J.P., Liu, J., et al. Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeys. Science 349 (2015), 320–324.
6. Barouch, D.H., Liu, J., Li, H., Maxfield, L.F., Abbink, P., Lynch, D.M., Iampietro, M.J., SanMiguel, A., Seaman, M.S., Ferrari, G., et al. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature 482 (2012), 89–93.
7. Barouch, D.H., Stephenson, K.E., Borducchi, E.N., Smith, K., Stanley, K., McNally, A.G., Liu, J., Abbink, P., Maxfield, L.F., Seaman, M.S., et al. Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155 (2013), 531–539.
8. Bonsignori, M., Kreider, E.F., Fera, D., Meyerhoff, R.R., Bradley, T., Wiehe, K., Alam, S.M., Aussedat, B., Walkowicz, W.E., Hwang, K.K., et al. Staged induction of HIV-1 glycan-dependent broadly neutralizing antibodies. Sci. Transl. Med., 9, 2017, eaai7514.
9. Bonsignori, M., Liao, H.X., Gao, F., Williams, W.B., Alam, S.M., Montefiori, D.C., Haynes, B.F., Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 275 (2017), 145–160.
10. Bonsignori, M., Zhou, T., Sheng, Z., Chen, L., Gao, F., Joyce, M.G., Ozorowski, G., Chuang, G.Y., Schramm, C.A., Wiehe, K., et al., NISC Comparative Sequencing Program. Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-Mimic antibody. Cell 165 (2016), 449–463.
11. Bontjer, I., Melchers, M., Tong, T., van Montfort, T., Eggink, D., Montefiori, D., Olson, W.C., Moore, J.P., Binley, J.M., Berkhout, B., Sanders, R.W., Comparative immunogenicity of evolved V1V2-deleted HIV-1 envelope glycoprotein trimers. PLoS One, 8, 2013, e67484.
12. Borrow, P., Moody, M.A., Immunologic characteristics of HIV-infected individuals who make broadly neutralizing antibodies. Immunol. Rev. 275 (2017), 62–78.
13. Bournazos, S., Klein, F., Pietzsch, J., Seaman, M.S., Nussenzweig, M.C., Ravetch, J.V., Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158 (2014), 1243–1253.
14. Bournazos, S., Ravetch, J.V., Anti-retroviral antibody FcγR-mediated effector functions. Immunol. Rev. 275 (2017), 285–295.
15. Bradley, T., Pollara, J., Santra, S., Vandergrift, N., Pittala, S., Bailey-Kellogg, C., Shen, X., Parks, R., Goodman, D., Eaton, A., et al. Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge. Nat. Commun., 8, 2017, 15711.
16. Burton, D.R., Ahmed, R., Barouch, D.H., Butera, S.T., Crotty, S., Godzik, A., Kaufmann, D.E., McElrath, M.J., Nussenzweig, M.C., Pulendran, B., et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 12 (2012), 396–407.
17. Burton, D.R., Hangartner, L., Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34 (2016), 635–659.
18. Burton, D.R., Hessell, A.J., Keele, B.F., Klasse, P.J., Ketas, T.A., Moldt, B., Dunlop, D.C., Poignard, P., Doyle, L.A., Cavacini, L., et al. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proc. Natl. Acad. Sci. USA 108 (2011), 11181–11186.
19. Burton, D.R., Mascola, J.R., Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16 (2015), 571–576.
20. Cao, L., Diedrich, J.K., Kulp, D.W., Pauthner, M., He, L., Park, S.R., Sok, D., Su, C.Y., Delahunty, C.M., Menis, S., et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat. Commun., 8, 2017, 14954.
21. Cardozo, T., Wang, S., Jiang, X., Kong, X.P., Hioe, C., Krachmarov, C., Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. Vaccine 32 (2014), 4916–4924.
22. Chan, Y.N., Boesch, A.W., Osei-Owusu, N.Y., Emileh, A., Crowley, A.R., Cocklin, S.L., Finstad, S.L., Linde, C.H., Howell, R.A., Zentner, I., et al. IgG binding characteristics of Rhesus Macaque FcγR. J. Immunol. 197 (2016), 2936–2947.
23. Chung, A.W., Crispin, M., Pritchard, L., Robinson, H., Gorny, M.K., Yu, X., Bailey-Kellogg, C., Ackerman, M.E., Scanlan, C., Zolla-Pazner, S., Alter, G., Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function. AIDS 28 (2014), 2523–2530.
24. Chung, A.W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.S., Schoen, M.K., Rolland, M., Suscovich, T.J., et al. Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines. Sci. Transl. Med., 6, 2014, 228ra38.
25. Chung, A.W., Kumar, M.P., Arnold, K.B., Yu, W.H., Schoen, M.K., Dunphy, L.J., Suscovich, T.J., Frahm, N., Linde, C., Mahan, A.E., et al. Dissecting polyclonal vaccine-induced humoral immunity against HIV using systems serology. Cell 163 (2015), 988–998.
26. Ciabattini, A., Pettini, E., Fiorino, F., Pastore, G., Andersen, P., Pozzi, G., Medaglini, D., Modulation of primary immune response by different vaccine adjuvants. Front. Immunol., 7, 2016, 427.
27. Coffman, R.L., Sher, A., Seder, R.A., Vaccine adjuvants: putting innate immunity to work. Immunity 33 (2010), 492–503.
28. Corey, L., Gilbert, P.B., Tomaras, G.D., Haynes, B.F., Pantaleo, G., Fauci, A.S., Immune correlates of vaccine protection against HIV-1 acquisition. Sci. Transl. Med., 7, 2015, 310rv7.
29. Corey, L., McElrath, M.J., Kublin, J.G., Post-step modifications for research on HIV vaccines. AIDS 23 (2009), 3–8.
30. Crotty, S., A brief history of T cell help to B cells. Nat. Rev. Immunol. 15 (2015), 185–189.
31. Delany, I., Rappuoli, R., Seib, K.L., Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb. Perspect. Med., 3, 2013, a012476.
32. Dormitzer, P.R., Ulmer, J.B., Rappuoli, R., Structure-based antigen design: a strategy for next generation vaccines. Trends Biotechnol. 26 (2008), 659–667.
33. Dosenovic, P., von Boehmer, L., Escolano, A., Jardine, J., Freund, N.T., Gitlin, A.D., McGuire, A.T., Kulp, D.W., Oliveira, T., Scharf, L., et al. Immunization for HIV-1 broadly neutralizing antibodies in human Ig knockin mice. Cell 161 (2015), 1505–1515.
34. Escolano, A., Steichen, J.M., Dosenovic, P., Kulp, D.W., Golijanin, J., Sok, D., Freund, N.T., Gitlin, A.D., Oliveira, T., Araki, T., et al. Sequential immunization elicits broadly neutralizing anti-HIV-1 antibodies in Ig knockin mice. Cell 166 (2016), 1445–1458.e12.
35. Fouts, T.R., Bagley, K., Prado, I.J., Bobb, K.L., Schwartz, J.A., Xu, R., Zagursky, R.J., Egan, M.A., Eldridge, J.H., LaBranche, C.C., et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc. Natl. Acad. Sci. USA 112 (2015), E992–E999.
36. Francica, J.R., Zak, D.E., Linde, C., Siena, E., Johnson, C., Juraska, M., Yates, N.L., Gunn, B., De Gregorio, E., Flynn, B.J., et al. Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs. Blood Adv. 1 (2017), 2329–2342.
37. Francis, D.P., Heyward, W.L., Popovic, V., Orozco-Cronin, P., Orelind, K., Gee, C., Hirsch, A., Ippolito, T., Luck, A., Longhi, M., et al. Candidate HIV/AIDS vaccines: lessons learned from the World's first phase III efficacy trials. AIDS 17 (2003), 147–156.
38. Gautam, R., Nishimura, Y., Gaughan, N., Gazumyan, A., Schoofs, T., Buckler-White, A., Seaman, M.S., Swihart, B.J., Follmann, D.A., Nussenzweig, M.C., Martin, M.A., A single injection of crystallizable fragment domain-modified antibodies elicits durable protection from SHIV infection. Nat. Med. 24 (2018), 610–616.
39. Gautam, R., Nishimura, Y., Pegu, A., Nason, M.C., Klein, F., Gazumyan, A., Golijanin, J., Buckler-White, A., Sadjadpour, R., Wang, K., et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533 (2016), 105–109.
40. Gordon, S.N., Liyanage, N.P., Doster, M.N., Vaccari, M., Vargas-Inchaustegui, D.A., Pegu, P., Schifanella, L., Shen, X., Tomaras, G.D., Rao, M., et al. Boosting of ALVAC-SIV vaccine-primed macaques with the CD4-SIVgp120 fusion protein elicits antibodies to V2 associated with a decreased risk of SIVmac251 acquisition. J. Immunol. 197 (2016), 2726–2737.
41. Gray, E.S., Moore, P.L., Choge, I.A., Decker, J.M., Bibollet-Ruche, F., Li, H., Leseka, N., Treurnicht, F., Mlisana, K., Shaw, G.M., et al., CAPRISA 002 Study Team. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81 (2007), 6187–6196.
42. Gray, G.E., Laher, F., Lazarus, E., Ensoli, B., Corey, L., Approaches to preventative and therapeutic HIV vaccines. Curr. Opin. Virol. 17 (2016), 104–109.
43. Guarecuco, R., Lu, J., McHugh, K.J., Norman, J.J., Thapa, L.S., Lydon, E., Langer, R., Jaklenec, A., Immunogenicity of pulsatile-release PLGA microspheres for single-injection vaccination. Vaccine 36 (2018), 3161–3168.
44. Hammer, S.M., Sobieszczyk, M.E., Janes, H., Karuna, S.T., Mulligan, M.J., Grove, D., Koblin, B.A., Buchbinder, S.P., Keefer, M.C., Tomaras, G.D., et al., HVTN 505 Study Team. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N. Engl. J. Med. 369 (2013), 2083–2092.
45. Haynes, B.F., Fleming, J., St Clair, E.W., Katinger, H., Stiegler, G., Kunert, R., Robinson, J., Scearce, R.M., Plonk, K., Staats, H.F., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308 (2005), 1906–1908.
46. Haynes, B.F., Gilbert, P.B., McElrath, M.J., Zolla-Pazner, S., Tomaras, G.D., Alam, S.M., Evans, D.T., Montefiori, D.C., Karnasuta, C., Sutthent, R., et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366 (2012), 1275–1286.
47. Haynes, B.F., Kelsoe, G., Harrison, S.C., Kepler, T.B., B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 30 (2012), 423–433.
48. Hessell, A.J., Hangartner, L., Hunter, M., Havenith, C.E., Beurskens, F.J., Bakker, J.M., Lanigan, C.M., Landucci, G., Forthal, D.N., Parren, P.W., et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449 (2007), 101–104.
49. Hessell, A.J., Rakasz, E.G., Poignard, P., Hangartner, L., Landucci, G., Forthal, D.N., Koff, W.C., Watkins, D.I., Burton, D.R., Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog., 5, 2009, e1000433.
50. Hoot, S., McGuire, A.T., Cohen, K.W., Strong, R.K., Hangartner, L., Klein, F., Diskin, R., Scheid, J.F., Sather, D.N., Burton, D.R., Stamatatos, L., Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. PLoS Pathog., 9, 2013, e1003106.
51. Jardine, J., Julien, J.P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.S., MacPherson, S., Jones, M., et al. Rational HIV immunogen design to target specific germline B cell receptors. Science 340 (2013), 711–716.
52. Jardine, J.G., Ota, T., Sok, D., Pauthner, M., Kulp, D.W., Kalyuzhniy, O., Skog, P.D., Thinnes, T.C., Bhullar, D., Briney, B., et al. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen. Science 349 (2015), 156–161.
53. Jennewein, M.F., Alter, G., The immunoregulatory roles of antibody glycosylation. Trends Immunol. 38 (2017), 358–372.
54. Julg, B., Liu, P.T., Wagh, K., Fischer, W.M., Abbink, P., Mercado, N.B., Whitney, J.B., Nkolola, J.P., McMahan, K., Tartaglia, L.J., et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl. Med., 9, 2017, eaao4235.
55. Julg, B., Sok, D., Schmidt, S.D., Abbink, P., Newman, R.M., Broge, T., Linde, C., Nkolola, J., Le, K., Su, D., et al. Protective efficacy of broadly neutralizing antibodies with incomplete neutralization activity against simian-human immunodeficiency virus in rhesus monkeys. J. Virol., 91, 2017 e01187-17.
56. Kanda, Y., Yamada, T., Mori, K., Okazaki, A., Inoue, M., Kitajima-Miyama, K., Kuni-Kamochi, R., Nakano, R., Yano, K., Kakita, S., et al. Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. Glycobiology 17 (2007), 104–118.
57. Kanda, Y., Yamane-Ohnuki, N., Sakai, N., Yamano, K., Nakano, R., Inoue, M., Misaka, H., Iida, S., Wakitani, M., Konno, Y., et al. Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. Biotechnol. Bioeng. 94 (2006), 680–688.
58. Kao, D., Lux, A., Schaffert, A., Lang, R., Altmann, F., Nimmerjahn, F., IgG subclass and vaccination stimulus determine changes in antigen specific antibody glycosylation in mice. Eur. J. Immunol. 47 (2017), 2070–2079.
59. King, N.P., Bale, J.B., Sheffler, W., McNamara, D.E., Gonen, S., Gonen, T., Yeates, T.O., Baker, D., Accurate design of co-assembling multi-component protein nanomaterials. Nature 510 (2014), 103–108.
60. Klasse, P.J., Ketas, T.J., Cottrell, C.A., Ozorowski, G., Debnath, G., Camara, D., Francomano, E., Pugach, P., Ringe, R.P., LaBranche, C.C., et al. Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques. PLoS Pathog., 14, 2018, e1006913.
61. Klein, F., Diskin, R., Scheid, J.F., Gaebler, C., Mouquet, H., Georgiev, I.S., Pancera, M., Zhou, T., Incesu, R.B., Fu, B.Z., et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153 (2013), 126–138.
62. Konno, Y., Kobayashi, Y., Takahashi, K., Takahashi, E., Sakae, S., Wakitani, M., Yamano, K., Suzawa, T., Yano, K., Ohta, T., et al. Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity. Cytotechnology 64 (2012), 249–265.
63. Kovacs, J.M., Noeldeke, E., Ha, H.J., Peng, H., Rits-Volloch, S., Harrison, S.C., Chen, B., Stable, uncleaved HIV-1 envelope glycoprotein gp140 forms a tightly folded trimer with a native-like structure. Proc. Natl. Acad. Sci. USA 111 (2014), 18542–18547.
64. Li, H., Rhee, E.G., Masek-Hammerman, K., Teigler, J.E., Abbink, P., Barouch, D.H., Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys. J. Virol. 86 (2012), 10862–10865.
65. Li, Y., Cleveland, B., Klots, I., Travis, B., Richardson, B.A., Anderson, D., Montefiori, D., Polacino, P., Hu, S.L., Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J. Virol. 82 (2008), 638–651.
66. Liao, H.X., Lynch, R., Zhou, T., Gao, F., Alam, S.M., Boyd, S.D., Fire, A.Z., Roskin, K.M., Schramm, C.A., Zhang, Z., et al., NISC Comparative Sequencing Program. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496 (2013), 469–476.
67. Lin, L., Finak, G., Ushey, K., Seshadri, C., Hawn, T.R., Frahm, N., Scriba, T.J., Mahomed, H., Hanekom, W., Bart, P.A., et al. COMPASS identifies T-cell subsets correlated with clinical outcomes. Nat. Biotechnol. 33 (2015), 610–616.
68. Liu, J., Ghneim, K., Sok, D., Bosche, W.J., Li, Y., Chipriano, E., Berkemeier, B., Oswald, K., Borducchi, E., Cabral, C., et al. Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353 (2016), 1045–1049.
69. Loré, K., Karlsson Hedestam, G.B., Novel adjuvants for B cell immune responses. Curr. Opin. HIV AIDS 4 (2009), 441–446.
70. Lu, L.L., Suscovich, T.J., Fortune, S.M., Alter, G., Beyond binding: antibody effector functions in infectious diseases. Nat. Rev. Immunol. 18 (2018), 46–61.
71. Mahan, A.E., Jennewein, M.F., Suscovich, T., Dionne, K., Tedesco, J., Chung, A.W., Streeck, H., Pau, M., Schuitemaker, H., Francis, D., et al. Antigen-specific antibody glycosylation is regulated via vaccination. PLoS Pathog., 12, 2016, e1005456.
72. McCoy, L.E., van Gils, M.J., Ozorowski, G., Messmer, T., Briney, B., Voss, J.E., Kulp, D.W., Macauley, M.S., Sok, D., Pauthner, M., et al. Holes in the glycan shield of the native HIV envelope are a target of trimer-elicited neutralizing antibodies. Cell Rep. 16 (2016), 2327–2338.
73. McElrath, M.J., De Rosa, S.C., Moodie, Z., Dubey, S., Kierstead, L., Janes, H., Defawe, O.D., Carter, D.K., Hural, J., Akondy, R., et al., Step Study Protocol Team. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372 (2008), 1894–1905.
74. McGuire, A.T., Hoot, S., Dreyer, A.M., Lippy, A., Stuart, A., Cohen, K.W., Jardine, J., Menis, S., Scheid, J.F., West, A.P., et al. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210 (2013), 655–663.
75. McHugh, K.J., Nguyen, T.D., Linehan, A.R., Yang, D., Behrens, A.M., Rose, S., Tochka, Z.L., Tzeng, S.Y., Norman, J.J., Anselmo, A.C., et al. Fabrication of fillable microparticles and other complex 3D microstructures. Science 357 (2017), 1138–1142.
76. Mikell, I., Sather, D.N., Kalams, S.A., Altfeld, M., Alter, G., Stamatatos, L., Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog., 7, 2011, e1001251.
77. Mohanram, V., Demberg, T., Musich, T., Tuero, I., Vargas-Inchaustegui, D.A., Miller-Novak, L., Venzon, D., Robert-Guroff, M., B cell responses associated with vaccine-induced delayed SIVmac251 acquisition in female rhesus macaques. J. Immunol. 197 (2016), 2316–2324.
78. Moldt, B., Rakasz, E.G., Schultz, N., Chan-Hui, P.Y., Swiderek, K., Weisgrau, K.L., Piaskowski, S.M., Bergman, Z., Watkins, D.I., Poignard, P., Burton, D.R., Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 109 (2012), 18921–18925.
79. Ouattara, A., Laurens, M.B., Vaccines against malaria. Clin. Infect. Dis. 60 (2015), 930–936.
80. Overdijk, M.B., Verploegen, S., Ortiz Buijsse, A., Vink, T., Leusen, J.H., Bleeker, W.K., Parren, P.W., Crosstalk between human IgG isotypes and murine effector cells. J. Immunol. 189 (2012), 3430–3438.
81. Pardi, N., Hogan, M.J., Naradikian, M.S., Parkhouse, K., Cain, D.W., Jones, L., Moody, M.A., Verkerke, H.P., Myles, A., Willis, E., et al. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J. Exp. Med. 215 (2018), 1571–1588.
82. Parren, P.W., Marx, P.A., Hessell, A.J., Luckay, A., Harouse, J., Cheng-Mayer, C., Moore, J.P., Burton, D.R., Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75 (2001), 8340–8347.
83. Pashine, A., Valiante, N.M., Ulmer, J.B., Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. 11:4, Suppl (2005), S63–S68.
84. Plotkin, S.A., Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47 (2008), 401–409.
85. Rajasekaran, N., Chester, C., Yonezawa, A., Zhao, X., Kohrt, H.E., Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment. ImmunoTargets Ther. 4 (2015), 91–100.
86. Rappuoli, R., Aderem, A., A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473 (2011), 463–469.
87. Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R., Premsri, N., Namwat, C., de Souza, M., Adams, E., et al., MOPH-TAVEG Investigators. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361 (2009), 2209–2220.
88. Rhee, E.G., Blattman, J.N., Kasturi, S.P., Kelley, R.P., Kaufman, D.R., Lynch, D.M., La Porte, A., Simmons, N.L., Clark, S.L., Pulendran, B., et al. Multiple innate immune pathways contribute to the immunogenicity of recombinant adenovirus vaccine vectors. J. Virol. 85 (2011), 315–323.
89. Richman, D.D., Wrin, T., Little, S.J., Petropoulos, C.J., Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 100 (2003), 4144–4149.
90. Roederer, M., Keele, B.F., Schmidt, S.D., Mason, R.D., Welles, H.C., Fischer, W., Labranche, C., Foulds, K.E., Louder, M.K., Yang, Z.Y., et al. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. Nature 505 (2014), 502–508.
91. Rutten, L., Lai, Y.T., Blokland, S., Truan, D., Bisschop, I.J.M., Strokappe, N.M., Koornneef, A., van Manen, D., Chuang, G.Y., Farney, S.K., et al. A universal Approach to optimize the folding and stability of prefusion-closed HIV-1 envelope trimers. Cell Rep. 23 (2018), 584–595.
92. Sanders, R.W., van Gils, M.J., Derking, R., Sok, D., Ketas, T.J., Burger, J.A., Ozorowski, G., Cupo, A., Simonich, C., Goo, L., et al. HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers. Science, 349, 2015, aac4223.
93. Santra, S., Tomaras, G.D., Warrier, R., Nicely, N.I., Liao, H.X., Pollara, J., Liu, P., Alam, S.M., Zhang, R., Cocklin, S.L., et al. Human non-neutralizing HIV-1 envelope monoclonal antibodies limit the number of founder viruses during SHIV mucosal infection in Rhesus Macaques. PLoS Pathog., 11, 2015, e1005042.
94. Sather, D.N., Armann, J., Ching, L.K., Mavrantoni, A., Sellhorn, G., Caldwell, Z., Yu, X., Wood, B., Self, S., Kalams, S., Stamatatos, L., Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83 (2009), 757–769.
95. Schwab, I., Nimmerjahn, F., Intravenous immunoglobulin therapy: how does IgG modulate the immune system?. Nat. Rev. Immunol. 13 (2013), 176–189.
96. Scott, A.M., Allison, J.P., Wolchok, J.D., Monoclonal antibodies in cancer therapy. Cancer Immun., 12, 2012, 14.
97. Sekaly, R.P., The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 205 (2008), 7–12.
98. Sevy, A.M., Panda, S., Crowe, J.E. Jr., Meiler, J., Vorobeychik, Y., Integrating linear optimization with structural modeling to increase HIV neutralization breadth. PLoS Comput. Biol., 14, 2018, e1005999.
99. Sips, M., Krykbaeva, M., Diefenbach, T.J., Ghebremichael, M., Bowman, B.A., Dugast, A.S., Boesch, A.W., Streeck, H., Kwon, D.S., Ackerman, M.E., et al. Fc receptor-mediated phagocytosis in tissues as a potent mechanism for preventive and therapeutic HIV vaccine strategies. Mucosal Immunol. 9 (2016), 1584–1595.
100. Sok, D., Briney, B., Jardine, J.G., Kulp, D.W., Menis, S., Pauthner, M., Wood, A., Lee, E.C., Le, K.M., Jones, M., et al. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice. Science 353 (2016), 1557–1560.
101. Stadlmann, J., Pabst, M., Kolarich, D., Kunert, R., Altmann, F., Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 8 (2008), 2858–2871.
102. Steinbrook, R., One step forward, two steps back—will there ever be an AIDS vaccine?. N. Engl. J. Med. 357 (2007), 2653–2655.
103. Stephenson, K.E., Barouch, D.H., A global approach to HIV-1 vaccine development. Immunol. Rev. 254 (2013), 295–304.
104. Stephenson, K.E., D'Couto, H.T., Barouch, D.H., New concepts in HIV-1 vaccine development. Curr. Opin. Immunol. 41 (2016), 39–46.
105. + T cell responses in HIV vaccine development. Nat. Med. 19 (2013), 143–149.
106. + T cells in immunity to viruses. Nat. Rev. Immunol. 12 (2012), 136–148.
107. Teigler, J.E., Iampietro, M.J., Barouch, D.H., Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys. J. Virol. 86 (2012), 9590–9598.
108. Teigler, J.E., Kagan, J.C., Barouch, D.H., Late endosomal trafficking of alternative serotype adenovirus vaccine vectors augments antiviral innate immunity. J. Virol. 88 (2014), 10354–10363.
109. Veazey, R.S., Shattock, R.J., Pope, M., Kirijan, J.C., Jones, J., Hu, Q., Ketas, T., Marx, P.A., Klasse, P.J., Burton, D.R., Moore, J.P., Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat. Med. 9 (2003), 343–346.
110. Verkoczy, L., Chen, Y., Zhang, J., Bouton-Verville, H., Newman, A., Lockwood, B., Scearce, R.M., Montefiori, D.C., Dennison, S.M., Xia, S.M., et al. Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responses. J. Immunol. 191 (2013), 2538–2550.
111. Wang, J., Tong, P., Lu, L., Zhou, L., Xu, L., Jiang, S., Chen, Y.H., HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies. PLoS One, 6, 2011, e18233.
112. Wang, W., Erbe, A.K., Hank, J.A., Morris, Z.S., Sondel, P.M., NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy. Front. Immunol., 6, 2015, 368.
113. Yu, W.H., Zhao, P., Draghi, M., Arevalo, C., Karsten, C.B., Suscovich, T.J., Gunn, B., Streeck, H., Brass, A.L., Tiemeyer, M., et al. Exploiting glycan topography for computational design of Env glycoprotein antigenicity. PLoS Comput. Biol., 2018, 10.1371/journal.pcbi.1006093 Published online April 20, 2018.
114. Williams, W.B., Zhang, J., Jiang, C., Nicely, N.I., Fera, D., Luo, K., Moody, M.A., Liao, H.X., Alam, S.M., Kepler, T.B., et al. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations. Nat. Commun., 8, 2017, 1732.
115. Xiao, X., Chen, W., Feng, Y., Zhu, Z., Prabakaran, P., Wang, Y., Zhang, M.Y., Longo, N.S., Dimitrov, D.S., Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem. Biophys. Res. Commun. 390 (2009), 404–409.
116. Xu, K., Acharya, P., Kong, R., Cheng, C., Chuang, G.Y., Liu, K., Louder, M.K., O'Dell, S., Rawi, R., Sastry, M., et al. Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1. Nat. Med. 24 (2018), 857–867.
117. Zhou, T., Lynch, R.M., Chen, L., Acharya, P., Wu, X., Doria-Rose, N.A., Joyce, M.G., Lingwood, D., Soto, C., Bailer, R.T., et al., NISC Comparative Sequencing Program. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161 (2015), 1280–1292.